These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 22157930)

  • 1. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
    Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
    Mod Pathol; 2012 Apr; 25(4):615-24. PubMed ID: 22157930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas.
    Yamamoto S; Tsuda H; Miyai K; Takano M; Tamai S; Matsubara O
    Mod Pathol; 2012 Jan; 25(1):122-30. PubMed ID: 21983935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
    Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
    Virchows Arch; 2012 Jan; 460(1):77-87. PubMed ID: 22120431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?
    Samartzis EP; Samartzis N; Noske A; Fedier A; Caduff R; Dedes KJ; Fink D; Imesch P
    Mod Pathol; 2012 Jun; 25(6):885-92. PubMed ID: 22301703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
    Guan B; Mao TL; Panuganti PK; Kuhn E; Kurman RJ; Maeda D; Chen E; Jeng YM; Wang TL; Shih IeM
    Am J Surg Pathol; 2011 May; 35(5):625-32. PubMed ID: 21412130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
    N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
    Yamamoto S; Tsuda H; Takano M; Iwaya K; Tamai S; Matsubara O
    J Pathol; 2011 Oct; 225(2):189-94. PubMed ID: 21735444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
    Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
    J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
    BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
    Ayhan A; Mao TL; Seckin T; Wu CH; Guan B; Ogawa H; Futagami M; Mizukami H; Yokoyama Y; Kurman RJ; Shih IeM
    Int J Gynecol Cancer; 2012 Oct; 22(8):1310-5. PubMed ID: 22976498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.
    Wu CH; Mao TL; Vang R; Ayhan A; Wang TL; Kurman RJ; Shih IeM
    Int J Gynecol Pathol; 2012 Jul; 31(4):297-303. PubMed ID: 22653341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8
    Heinze K; Nazeran TM; Lee S; Krämer P; Cairns ES; Chiu DS; Leung SC; Kang EY; Meagher NS; Kennedy CJ; Boros J; Kommoss F; Vollert HW; Heitz F; du Bois A; Harter P; Grube M; Kraemer B; Staebler A; Kommoss FK; Heublein S; Sinn HP; Singh N; Laslavic A; Elishaev E; Olawaiye A; Moysich K; Modugno F; Sharma R; Brand AH; Harnett PR; DeFazio A; Fortner RT; Lubinski J; Lener M; Tołoczko-Grabarek A; Cybulski C; Gronwald H; Gronwald J; Coulson P; El-Bahrawy MA; Jones ME; Schoemaker MJ; Swerdlow AJ; Gorringe KL; Campbell I; Cook L; Gayther SA; Carney ME; Shvetsov YB; Hernandez BY; Wilkens LR; Goodman MT; Mateoiu C; Linder A; Sundfeldt K; Kelemen LE; Gentry-Maharaj A; Widschwendter M; Menon U; Bolton KL; Alsop J; Shah M; Jimenez-Linan M; Pharoah PD; Brenton JD; Cushing-Haugen KL; Harris HR; Doherty JA; Gilks B; Ghatage P; Huntsman DG; Nelson GS; Tinker AV; Lee CH; Goode EL; Nelson BH; Ramus SJ; Kommoss S; Talhouk A; Köbel M; Anglesio MS
    J Pathol; 2022 Apr; 256(4):388-401. PubMed ID: 34897700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
    Huang HN; Chiang YC; Cheng WF; Chen CA; Lin MC; Kuo KT
    Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
    Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
    Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden.
    Anglesio MS; Bashashati A; Wang YK; Senz J; Ha G; Yang W; Aniba MR; Prentice LM; Farahani H; Li Chang H; Karnezis AN; Marra MA; Yong PJ; Hirst M; Gilks B; Shah SP; Huntsman DG
    J Pathol; 2015 Jun; 236(2):201-9. PubMed ID: 25692284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
    Su YF; Tsai EM; Chen CC; Wu CC; Er TK
    Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors.
    Yamamoto S; Tsuda H; Takano M; Kita T; Kudoh K; Furuya K; Tamai S; Matsubara O
    Mod Pathol; 2008 Feb; 21(2):115-24. PubMed ID: 18084257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic Significance of HNF-1β, AIRD1A, and PIK3CA Expression in Ovarian Clear Cell Carcinoma: A Tissue Microarray Study of 130 Cases.
    Ye S; Yang J; You Y; Cao D; Huang H; Wu M; Chen J; Lang J; Shen K
    Medicine (Baltimore); 2016 Mar; 95(9):e3003. PubMed ID: 26945423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
    Samartzis EP; Noske A; Dedes KJ; Fink D; Imesch P
    Int J Mol Sci; 2013 Sep; 14(9):18824-49. PubMed ID: 24036443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component.
    Nishikimi K; Kiyokawa T; Tate S; Iwamoto M; Shozu M
    Histopathology; 2015 Dec; 67(6):866-71. PubMed ID: 25913291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.